Market
In how many countries will AstraZeneca and Daiichi Sankyo's treatment be approved by end of 2025?
2
Resolution / Starting Odds
Less than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
Regulatory approval announcements from AstraZeneca and Daiichi Sankyo
Story
AstraZeneca and Daiichi Sankyo Win First U.S. Approval for Novel Breast Cancer Treatment; Stock Rises Most in Five Months
Jan 19, 2025, 05:37 PM
AstraZeneca and Daiichi Sankyo have received U.S. approval for a novel breast cancer treatment, marking a significant milestone in their efforts to establish the drug as a widely used option in oncology. This approval represents the first authorization for this closely monitored treatment, which has prompted a notable increase in Daiichi Sankyo's stock, rising the most in five months. The approval was confirmed by multiple sources, including the FDA and various news outlets.
View original story
Similar markets
2 • 25%
1 • 25%
3 or more • 25%
0 • 25%
10 to 20 • 25%
More than 30 • 25%
Less than 10 • 25%
21 to 30 • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
11 to 15 • 25%
Less than 5 • 25%
5 to 10 • 25%
More than 15 • 25%
11-15 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
More than 15 countries • 25%
20 to 30 • 25%
More than 40 • 25%
Less than 20 • 25%
31 to 40 • 25%
Fewer than 30 countries • 25%
More than 90 countries • 25%
60 to 90 countries • 25%
30 to 60 countries • 25%
Less than 50 • 25%
50 to 80 • 25%
81 to 120 • 25%
More than 120 • 25%
10 or more countries • 25%
4-6 countries • 25%
1-3 countries • 25%
7-9 countries • 25%
More than 60 • 25%
40 to 60 • 25%
20 to 40 • 25%
Less than 20 • 25%